Skip to main content

Advertisement

SpringerLink
Log in

CHOP plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term Benefits: A Case Report and Literature Review

  • CASE
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of non-Hodgkin’s lymphoma characterized by an aggressive phenotype and poor outcome in the vast majority of cases. Substantial portions of patients have either no prior diagnosis of celiac disease or have a subacute course of celiac disease followed by EATL diagnosis. We report a case of a 72-year-old African American male without history of gastrointestinal intolerance who presented with acute abdominal pain and weight loss leading to the eventual diagnosis of gastric EATL. Despite an initial promising clinical and radiographic response to cyclophosphamide, doxorubicin, vincristine, and prednisone plus alemtuzumab, the disease rapidly progressed with a fatal outcome. This case and review of the literature highlights the features of this uncommon disease and addresses both the diagnostic and therapeutic challenges of this aggressive malignancy. We also discuss our experience with the use of fluoro-2-deoxy-d-glucose positron emission tomography in monitoring treatment response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Al-Toma A, Verbeek WH, Hadithi M, et al. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut. 2007;56:1373–8.

    Article  PubMed  CAS  Google Scholar 

  2. Alaedini A, Green PH. Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med. 2005;142:289–98.

    PubMed  CAS  Google Scholar 

  3. Anderson RP, Degano P, Godkin AJ, et al. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med. 2000;6:337–42.

    Article  PubMed  CAS  Google Scholar 

  4. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  5. Daum S, Weiss D, Hummel M, et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut. 2001;49:804–12.

    Article  PubMed  CAS  Google Scholar 

  6. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920–4.

    Article  PubMed  CAS  Google Scholar 

  7. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;120:636–51.

    Article  PubMed  CAS  Google Scholar 

  8. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18:795–803.

    PubMed  CAS  Google Scholar 

  9. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  PubMed  CAS  Google Scholar 

  10. Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357:1731–43.

    Article  PubMed  CAS  Google Scholar 

  11. Honemann D, Prince HM, Hicks RJ, et al. Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Ann Hematol. 2005;84:118–21.

    Article  PubMed  Google Scholar 

  12. Obermann EC, Diss TC, Hamoudi RA, et al. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma. J Pathol. 2004;202:252–62.

    Article  PubMed  CAS  Google Scholar 

  13. Verbeek WH, Mulder CJ, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med. 2006;355:1396–7. author reply 1397.

    Article  PubMed  CAS  Google Scholar 

  14. Vivas S, Ruiz de Morales JM, Ramos F, et al. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med. 2006;354:2514–5.

    Article  PubMed  CAS  Google Scholar 

  15. Wohrer S, Chott A, Drach J, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol. 2004;15:1680–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Chicago Hospitals, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637, USA

    Sheetal M. Kircher & Sandeep Gurbuxani

  2. Section of Hematology/Oncology, Department of Medicine, University of Chicago Hospitals, Chicago, IL, USA

    Sonali M. Smith

Authors
  1. Sheetal M. Kircher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandeep Gurbuxani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonali M. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonali M. Smith.

Additional information

Copyright Statement

I verify that this article is original, is not under consideration, has not been published previously elsewhere, and that its content has not been anticipated by any previous publication.

Sonali M. Smith, MD

Sheetal M. Kircher, MD

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kircher, S.M., Gurbuxani, S. & Smith, S.M. CHOP plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term Benefits: A Case Report and Literature Review. J Gastrointest Canc 38, 19–23 (2007). https://doi.org/10.1007/s12029-008-9009-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-008-9009-z

Keywords

Search

Navigation